|
| 利塞膦酸钠和阿仑膦酸钠治疗对股骨粗隆下侧皮质骨密度变化的影响对比研究 |
| Comparative study on the effects of risedronate and alendronate on bone mineral density in the femoral subtrochanteric lateral cortex |
| |
| DOI：10.3969/j.issn.1006-7108.2019.06.024 |
| 中文关键词: 阿仑膦酸钠 骨密度 股骨 利塞膦酸盐 骨质疏松 |
| 英文关键词:alendronate bone mineral density femur risedronate osteoporosis |
| 基金项目: |
|
| 摘要点击次数: 1381 |
| 全文下载次数: 577 |
| 中文摘要: |
| 目的 回顾性评估利塞膦酸钠和阿仑膦酸钠治疗对股骨粗隆下侧皮质(subtrochanteric lateral cortex，STLC)骨密度(bone mineral density，BMD)变化的影响。方法 共有168例受试者，使用双能X线骨密度仪(dual energy X-ray absorptiometry，DXA)对其BMD进行2～4年间隔随访，纳入本次回顾性研究，分为3组：46例未服用任何抗骨质疏松药物(对照组)，69例使用阿仑膦酸钠(阿仑膦酸钠组)，53例使用利塞膦酸盐(利塞膦酸盐组)。通过在骨皮质上绘制矩形感兴趣区，在每位患者的STLC和转子下内侧皮质(subtrochanteric medial cortex，STMC)中测量BMD。通过使用协方差模型控制来分析STLC中BMD的百分比变化，以控制年龄、体质量指数、STMC百分比变化、髋轴长度、DXA检查之间的时间间隔的5个独立变量。结果 对照组、阿仑膦酸盐组和利塞膦酸盐组BMD的最小均数±标准差分别为1.47±1.51、2.24±1.27和6.98±1.23。与对照组(调整后的P=0.010)或阿仑膦酸盐组(调整后的P=0.011)相比，利塞膦酸盐组的STLC显示出更高的BMD百分比变化。结论：利塞膦酸盐组中STLC的BMD变化百分比大于阿仑膦酸盐组和对照组。 |
| 英文摘要: |
| Objective To evaluate the effect of risedronate and alendronate on bone mineral density (BMD) changes in the femoral subtrochanteric lateral cortex (STLC). Methods A total of 168 subjects, who had BMD follow-up at 2- to 4-year interval using dual energy X-ray absorptiometry (DXA), were included in this retrospective study and were divided into the following 3 groups: 46 patients did not take any anti-osteoporosis drugs (control group), 69 patients received alendronate (alendronate group), and 53 patients received risedronate (risedronate group). BMD was measured at the STLC and subtrochanteric medial cortex (STMC) in each patient by drawing rectangular ROIs at the bone cortices. The percent change of BMD at the STLC were compared between the aforementioned 3 groups by using analysis of covariance model adjusted for five independent variables including age, body mass index, percent change of STMC, hip axis length, and time interval between DXA examinations. Results The least square mean value± standard deviation of the percent change of BMD in the control, alendronate, and risedronate groups were 1.47±1.51, 2.24±1.27 and 6.98±1.23, respectively. The risedronate group showed significantly greater BMD percentage change compared with the control (adjusted P=0.010) or alendronate (adjusted P=0.011) groups. Conclusion The percent change of BMD at the STLC in the risedronate user group was greater than the alendronate and control groups. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |